02348.HK
Dawnrays Pharmaceutical (Holdings) Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.99
−1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3B | 1.2B | 1.1B | 1.2B | 1.3B |
| Cost of Revenue | 1.2B | 673.5M | 482.7M | 509.6M | 511.0M |
| Gross Profit | 1.1B | 557.4M | 577.6M | 641.5M | 766.7M |
| Operating Expenses | |||||
| R&D Expense | 144.1M | 83.5M | 70.8M | 90.8M | 79.5M |
| SG&A Expense | 478.3M | 244.3M | 254.5M | 260.3M | 264.8M |
| General & Admin Expense | 214.5M | 138.3M | 126.7M | 113.2M | 122.1M |
| Selling & Marketing Expense | 164.9M | 106.0M | 127.8M | 147.0M | 142.7M |
| Other Expenses | 29.2M | — | (115.6M) | (151.9M) | — |
| Total Operating Expenses | 651.6M | 327.8M | 209.7M | 199.2M | 344.3M |
| Cost and Expenses | 1.8B | 1.0B | 692.4M | 873.7M | 858.8M |
| Operating Income (EBIT) | 402.3M | 229.6M | 367.9M | 277.4M | 422.4M |
| Non-Operating | |||||
| Interest Income | 64.0M | 30.3M | 36.4M | 25.9M | 19.4M |
| Interest Expense | 753.9K | 496.0K | 3.6M | 989.0K | 371.0K |
| Net Interest Income | 63.3M | 29.8M | 32.8M | 24.9M | 19.0M |
| Other Non-Op Income/Expense | 83.5M | 20.0M | 269.0M | 136.6M | 16.0M |
| Non-Operating Income (excl Interest) | 2.0M | 2.2M | 165.9M | 27.3M | 3.3M |
| EBT (Pre-Tax Income) | 485.8M | 249.6M | 636.9M | 414.1M | 438.4M |
| Income Tax Expense | 81.9M | 38.5M | 74.2M | 91.4M | 82.6M |
| Bottom Line | |||||
| Net Income | 407.5M | 214.0M | 564.9M | 326.0M | 358.1M |
| Earnings from Cont. Ops | 403.9M | 211.1M | 562.8M | 322.7M | 355.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 407.5M | 214.0M | 564.9M | 326.0M | 358.1M |
| Per Share | |||||
| Basic EPS | HK$0.27 | HK$0.14 | HK$0.38 | HK$0.22 | HK$0.24 |
| Diluted EPS | HK$0.27 | HK$0.14 | HK$0.38 | HK$0.22 | HK$0.24 |
| Revenue Per Share | HK$1.50 | HK$0.82 | HK$0.70 | HK$0.77 | HK$0.85 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | 576.6M | 343.7M | 280.5M | 498.9M | 505.2M |
| D&A | 176.3M | 116.2M | 78.4M | 83.9M | 66.4M |
| EBIT | 400.3M | 227.4M | 202.1M | 415.0M | 438.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026